Secondary Logo

Journal Logo

The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease

Bittle, Polly A. MSN, ARNP, FNP-C

doi: 10.1097/01.NPR.0000512253.40369.ab
Feature: ORAL DIABETES AGENTS
Open

Abstract: There is a need for treatment options in patients with type 2 diabetes mellitus and kidney disease to achieve glucose targets without risk of hypoglycemia. This article describes management options for these patients using glucose-lowering therapies, in particular dipeptidyl peptidase-4 inhibitors.

There is a need for treatment options in patients with type 2 diabetes mellitus and kidney disease to achieve glucose targets without risk of hypoglycemia. This article describes management options for these patients using glucose lowering therapies, in particular dipeptidyl peptidase-4 inhibitors.

Polly A. Bittle is an NP, practice manager, chief operating officer, and clinical research director at Tampa Bay Nephrology Associates, Tampa, Fla.

Writing and editorial support was provided by Linda Merkel, PhD of Envision Scientific Solutions, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the manuscript for scientific accuracy as well as intellectual property considerations. The author would like to thank German Ramirez, MD, for his ongoing support and encouragement.

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

The author has disclosed that she has no financial relationships related to this article.

Figure

Figure

Chronic kidney disease (CKD) affects approximately 2 million individuals worldwide, and type 2 diabetes mellitus (T2DM) is its leading cause.1 With the prevalence of T2DM increasing steadily, CKD will continue to rise.1 Diabetic kidney disease (DKD) occurs in 20% to 40% of patients with diabetes mellitus and is defined as the presence of increased urinary albumin excretion ([UAE] a ratio of urinary albumin to creatinine 30 mg/g or more), decreased glomerular filtration rate ([GFR] less than 60 mL/min/1.73 m2), or both.2,3

Persistent increased UAE (30 mg/g to 299 mg/g) is a well-established marker for the development of DKD and increased cardiovascular disease (CVD) risk in patients with T2DM and in the general population.4 The incidence of end-stage renal disease (ESRD) in U.S. patients with diabetes mellitus increased to 30% between 1998 and 2012 reveals an urgent need for improved therapeutic options.5

A vital part of reducing the risk of DKD and preserving the kidney requires targeting glycated hemoglobin (HbA1C) levels to less than 7%.6,7 Numerous studies show that intensive glucose lowering may delay the onset and progression of albuminuria in T2DM.8,9 However, therapeutic choices for patients with T2DM and DKD can be limited because of the reduced renal clearance of some agents, which prolongs their half-life. Drug or metabolite accumulation may potentially increase the risk of adverse reactions.10

Therefore, some glucose-lowering agents are contraindicated in subjects with kidney insufficiency. Other agents require dosage adjustment and frequent monitoring to avoid adverse reactions (hypoglycemia, fluid retention and edema, weight gain, hepatic damage, or lactic acidosis), which may be more severe due to the underlying pathophysiology of DKD.11

Treatment strategies for patients with DKD should include reduction in BP, weight loss, diabetes and lipid management, protein restriction, smoking cessation, and lowering of urinary albumin levels. This article provides an overview of the management of DKD and appropriate glucose-lowering therapies for use in patients with T2DM.

Back to Top | Article Outline

Glycemic control

Because the DKD patient population is often excluded from clinical studies, optimal glycemic targets in patients with DKD are poorly understood. Clinical trials have demonstrated that lowering HbA1C to less than 7% can prevent the progression of albuminuria and microvascular complications.6,9,12,13

A broader HbA1C range may be suitable for select patients. Specifically, less strict glycemic control (HbA1C, 7% to less than 8%) is recommended for patients with a history of severe hypoglycemia, over age 60, limited life expectancy, advanced kidney disease, microvascular or macrovascular complications, extensive comorbid conditions, or a long duration of T2DM. Additional health status considerations for adults age 65 and older are impairment in activities of daily living or mild to moderate cognitive impairment.2,12

Back to Top | Article Outline

BP control

Hypertension is a common comorbidity in CKD and CVD.13 The United Kingdom Prospective Diabetes Study indicated that BP control can reduce the development of DKD.14 Patients randomized to tight BP control (mean achieved BP, 144/82 mm Hg) experienced a 32% reduction in diabetes-related mortality and a 44% reduction in stroke versus those assigned to less stringent BP control (mean achieved BP, 154/87 mm Hg).

In patients with T2DM and hypertension, treatment with either angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) can delay the onset of elevated albuminuria, a risk factor for CVD.15 In addition, ARBs (irbesartan and losartan) reduced the progression of albuminuria and ESRD in patients with T2DM independent of their BP effects.16,17 Data from the Heart Outcomes Prevention Evaluation (HOPE) and the Microalbuminuria, Cardiovascular, and Renal Outcomes (MICRO-HOPE) substudy demonstrated that the ACEI ramipril reduced the risk of overt nephropathy by 24% in patients with diabetes mellitus.18

Additionally, HOPE showed an improvement in cardiovascular outcomes. Ramipril treatment reduced the risk of the combined primary outcome of myocardial infarction (MI), stroke, and cardiovascular death by 25% after adjustment for changes in BP over a median follow-up of 4.5 years in patients with diabetes mellitus.18

For the treatment of patients with T2DM and hypertension, the American Diabetes Association (ADA) recommends either an ACEI or ARB (but not both).2 Multiple-drug therapy with renin-angiotensin-aldosterone system (RAAS) inhibition and a thiazide diuretic will likely be required to reach BP targets of less than 140/90 mm Hg.2,15 Lower systolic targets may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.12

Back to Top | Article Outline

Lowering albuminuria

Lowering albuminuria through BP reduction is associated with a decreased risk of progression to ESRD.2,19 A post-hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study concluded that a reduction in either albuminuria or BP is important for renal outcomes, and a reduction in both improved clinical outcomes.19

Several studies have demonstrated that multifactorial treatment with renin-angiotensin system blockade, aspirin, and lipid-lowering agents reduces the risk of albuminuria, declining kidney function, and adverse cardiovascular events.20 The ADA has combined the previous two categories of microalbuminuria (30 mg/day to 299 mg/day) and macroalbuminuria (300 mg/day or more) into one grouping of albuminuria, now defined as a urine albumin to creatinine ratio (UACR) of 30 mg/g or more and has recently updated recommendations for regular screening and management of DKD in patients with T2DM (see Screening and management suggestions in T2DM).2

Back to Top | Article Outline

Managing hyperglycemia

Metformin continues to be the drug of choice for patients with T2DM because of its demonstrated safety and low cost; its mainly renal elimination pathway makes it unsuitable for patients with severe CKD because of the rare risk of lactic acidosis.21 While the FDA has recently relaxed their labeling recommendations for metformin-containing products for use in patients with CKD, they are still contraindicated in patients with eGFR below 30 mL/min/1.73 m2.22

Table

Table

Table

Table

If metformin is not tolerated or contraindicated, second-line agents are recommended. Sulfonylureas undergo significant renal clearance and increase the risk of hypoglycemia in patients with CKD. Glipizide is the preferred agent for patients with stage 3 to 5 CKD; glyburide should be avoided in these patients due to its long duration of action.10 Thiazolidinediones, although not cleared via the kidney, are associated with fluid retention and edema, and should not be used in patients with heart failure and should be used with caution in those with CVD without heart failure. Initiation of thiazolidinediones in patients with established New York Heart Association Class III or IV heart failure is contraindicated, and thiazolidinedione use should be avoided in patients with symptomatic heart failure.23

Renal recommendations need to be considered for the glucagon-like peptide-1 (GLP-1) receptor agonists. Exenatide and exenatide extended release should not be used in patients with severe kidney impairment (creatinine clearance less than 30 mL/min) or ESRD, and should be used with caution in patients with moderate renal impairment or kidney transplantation.24,25 In patients with moderate renal impairment, caution is advised when initiating or escalating doses of exenatide or liraglutide.25,26 Lixisenatide should not be used in patients with ESRD.27 No dose adjustment is needed for albiglutide, dulaglutide, liraglutide, or lixisenatide in patients with renal impairment, but renal function needs to be monitored if patients display severe gastrointestinal reactions.26-29

The glucose-lowering efficacy of sodium glucose cotransporter 2 (SGLT2) inhibitors is dependent on kidney function, and lower efficacy can be expected with decreased eGFR. The FDA has added warnings regarding urosepsis, urinary tract infections, and kidney injury in all SGLT2 inhibitors' prescribing labels. Canagliflozin and empagliflozin are not recommended for patients with eGFR less than 45 mL/min/1.73 m2, and dapagliflozin should not be used when the eGFR is less than 60 mL/min/1.73 m2.30-32

Back to Top | Article Outline

Using DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the breakdown of GLP-1 and glucose-dependent insulinotropic peptide, two incretins pivotal for glucose regulation.

The four DPP-4 inhibitors currently approved for the treatment of T2DM in the United States include sitagliptin, saxagliptin, linagliptin, and alogliptin.33-49 These agents are effective at lowering HbA1C in patients age 60 and older with a long duration of T2DM (more than 10 years) and with moderate-to-severe kidney insufficiency, including ESRD and dialysis, while displaying a low propensity for hypoglycemia and weight neutrality.50,51

A meta-analysis of 10 trials of 12 to 52 weeks with 1,951 patients who had moderate-to-severe CKD demonstrated that DPP-4 inhibitor monotherapy reduced HbA1C by –0.52% versus placebo or no treatment and was not associated with an increased risk of hypoglycemia or weight gain.50 Compared with glipizide monotherapy, DPP-4 inhibitors showed no difference in HbA1C lowering but provided a lower incidence of hypoglycemia.50 There were no reported increases in body weight, incidents of severe adverse events, or total mortality.

Sitagliptin. This drug reduced HbA1C by 0.7% to 0.8% from baseline in several randomized studies in patients with CKD and resulted in fewer cases of hypoglycemia than the active comparator.37-39 Some trials also assessed changes in UAE or UACR and showed decreases with sitagliptin (mean change, –195 mg/g) versus placebo (457 mg/g).37 In a 52-week study, sitagliptin added to sulfonylureas decreased UAE by more than 50% (76.2 mg/g to 33.0 mg/g).52 One analysis showed that sitagliptin, as an add-on to metformin, was more likely to reduce UACR by more than 20% in patients with the highest baseline UACR levels (greater than 300 mg/g) than in those with lower baseline UACR levels (30 mg/g to 100 mg/g).53 A retrospective claims-based cohort study showed that treatment with sitagliptin did not increase the risk of acute kidney failure status.54

The recently completed Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) included patients with an eGFR of 30 mL/min/1.73 m2 or greater and assessed secondary kidney function outcomes.55 The mean baseline eGFR for all patients was 74.9 ± 21.1 mL/min/1.73 m2. Of those, 9.4% on sitagliptin and 9.3% on placebo had an eGFR less than 50 mL/min/1.73 m2. After 48 months, the mean change from baseline was greater in the sitagliptin group than in the placebo group (–4.0 ± 18.4 and –2.8 ± 18.3 mL/min/1.73 m2, respectively). This slightly lower eGFR with sitagliptin remained consistent over all visits .55 Additionally, an ongoing phase 4 trial will evaluate the effects of sitagliptin plus an ACEI or ARB on reducing microalbuminuria in patients with T2DM.

Saxagliptin. In a 52-week study of patients with T2DM and CKD, use of saxagliptin resulted in a greater adjusted mean decrease in HbA1C than placebo (treatment difference, –0.73%, P < 0.001), with comparable rates of hypoglycemia (29% versus 28%). Reductions in adjusted mean HbA1C values were numerically greater with saxagliptin 2.5 mg once daily versus placebo in patients with moderate and severe CKD; however, reductions were similar in those with ESRD.40

A prospective analysis of renal outcomes from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial was conducted in more than 16,000 patients with T2DM.56 Patients receiving saxagliptin in addition to usual care were more likely to demonstrate improvements in UACR compared with those receiving placebo (11% versus 9%, P < 0.01), with the most noteworthy improvement occurring among those with albumin levels of 30 mg/g to 300 mg/g at baseline. After 1 year, 31.3% versus 25.7% of patients receiving saxagliptin compared with placebo reverted to normoalbuminuria (P < 0.0001).56

Linagliptin. Treatment with this drug resulted in mean placebo-corrected reductions in HbA1C from –0.53% to –1.08% in six randomized controlled studies comprising patients with mild-to-severe CKD, with an incidence of severe hypoglycemia comparable to or lower than placebo.41-44,46,57 A recent retrospective analysis assessed data from two clinical trials in patients with T2DM and mild-to-severe CKD receiving linagliptin as an add-on to insulin.46 Placebo-adjusted mean HbA1C changes from baseline were –0.59% and –0.69% after 24 weeks in patients with mild and moderate kidney impairment, respectively, and –0.43% after 12 weeks in patients with severe kidney impairment.

The frequencies of severe hypoglycemia with linagliptin (2% to 6%) were similar to those of placebo (1% to 6%) in patients with mild, moderate, or severe kidney impairment, respectively.46 Data from this analysis show that the addition of linagliptin to insulin in patients with T2DM and CKD improved glycemic outcomes and was well tolerated. A pooled analysis of four studies involving 217 patients with T2DM and prevalent albuminuria (UACR, 30 mg/g to 3,000 mg/g creatinine) receiving linagliptin in addition to stable RAAS inhibitors found a significant reduction in albuminuria; this observation was independent of changes in glucose level or systolic BP.42

A meta-analysis of 13 phase 3 trials of linagliptin versus placebo in patients with T2DM evaluated renal outcomes using a composite primary endpoint of new-onset microalbuminuria, macroalbuminuria, CKD, acute kidney failure, and death by any cause.58 This composite endpoint was reached in 12.8% of patients receiving linagliptin compared with 15.6% of those receiving placebo (hazard ratio = 0.84).

MARLINA-T2D (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin), a prospectively designed, 24-week trial assessing the effects of linagliptin on albuminuria in patients with T2DM and persistent albuminuria (UACR, 30 mg/g to 3,000 mg/g), demonstrated improved glycemic control without any significant changes to the UACR.41

Alogliptin. This drug has been assessed in patients with T2DM and CKD in a few small studies.47,48 In a 48-week hemodialysis trial (n = 30), alogliptin significantly reduced HbA1C levels from a baseline of 7.1 ± 0.2% to 6.3 ± 0.2% (P < 0.0001) and was generally well tolerated.48 In 16 patients undergoing hemodialysis, long-term administration of alogliptin once daily for 24 months decreased HbA1C levels significantly (7.1% to 5.8%) and was well tolerated, but required renal dosing considerations and safety monitoring.47

This class of agents may present a viable choice for patients with T2DM and renal impairment.50,51 Whereas sitagliptin, saxagliptin, and alogliptin share renal elimination pathways and require dose adjustment in patients with moderate-to-severe renal impairment, linagliptin is primarily excreted via bile and gut and does not require dose adjustment for any level of kidney function. Warnings for DPP-4 inhibitors include the risk of acute pancreatitis, hypersensitivity reactions, severe and disabling arthralgia, and bullous pemphigoid. DPP-4 inhibitors should be discontinued if any of these conditions develop. Patients taking saxagliptin and alogliptin should be monitored for heart failure; if heart failure develops, treat the patient according to current standards of care and consider discontinuing the drug.59

Back to Top | Article Outline

Clinical practice considerations

Patients with T2DM and DKD often have other comorbidities (hypertension, dyslipidemia) that require a multifactorial treatment approach. Patients should be counseled on proper nutrition, such as reducing sodium and moderating protein and potassium intake; emphasizing vegetables, low-fat or nonfat dairy products, whole grains, nuts, legumes, fish, and poultry; and minimizing red meat.2 Lifestyle changes should be applied to all high-risk patients, including smoking cessation, weight loss, and exercise.

Patients require regular visits to screen and monitor for micro- and macrovascular complications in a coordinated team approach addressing both T2DM and CKD in order to minimize the risk of adverse cardiovascular events. Lowering plasma glucose and HbA1C levels remains an important component of disease management and end-organ disease prevention.

NPs must balance the benefits of antidiabetic agents with potential adverse reactions, such as hypoglycemia and weight gain. The choice of glucose-lowering agents in patients with DKD is limited because renal function affects the safety profile of many agents. Metformin, the first choice for treatment of T2DM in the general population, had severe restrictions regarding its use in CKD; however, the FDA recently relaxed the labeling for metformin-containing products, making them a treatment option for patients with eGFR greater than 60 mL/min/1.73 m2.22 Among the sulfonylureas, glyburide cannot be used in CKD, but glipizide and glimepiride (if initiated at a low dose) can be appropriate choices with weight neutrality and the convenience of once-daily dosing.60

Thiazolidinediones should not be used in patients with heart failure and should be used with caution in those with CVD without heart failure due to the associated risks of fluid retention and edema.23 Among the GLP-1 receptor agonists, exenatide should not be used in severe CKD and should be used with caution in kidney transplant patients.24,25 SGLT2 inhibitors have a lower efficacy with a decreased eGFR and are generally not recommended for an eGFR less than 45 to 60 mL/min/1.73 m2 because they rely on the ability of the kidneys to eliminate glucose.30-32 Of note, the FDA includes warnings regarding urosepsis, urinary tract infections, and kidney injury in all SGLT2 labels.2

Evidence from clinical trials suggests that DPP-4 inhibitor therapy is also a viable option for patients with T2DM and CKD, affording a lower incidence of hypoglycemia, without weight gain, compared with other agents.50 When combined with insulin secretagogues or insulin, dosage reduction is recommended to reduce the risk of hypoglycemia. Sitagliptin, saxagliptin, and alogliptin require dose adjustments in patients with moderate-to-severe renal impairment, whereas linagliptin is primarily excreted by bile and gut; therefore, no dose adjustment is required.59 In addition, data suggest that linagliptin may reduce albuminuria, a well-established risk factor for CKD and CVD, therefore offering NPs therapeutic options for this complex patient population.41,61

Because patients with T2DM and CKD are a diverse, difficult-to-treat population, an individualized treatment strategy should be utilized. This treatment plan necessitates commitment of the patient in terms of self-monitoring, and a variety of healthcare practitioners for ongoing educational reinforcement and a multifactorial treatment approach that includes medications, proper nutrition with meal planning, and physical activity. This approach will ensure the best possible outcome, with the least potential adverse reactions, improving patient adherence, long-term benefits, and overall cardiovascular risk reduction.

Back to Top | Article Outline

REFERENCES

1. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–1270.
2. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(suppl 1):S1–S135.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539.
4. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LGDEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–2063.
5. 2015 USRDS Annual Data Report | Volume 2—ESRD in the United States. http://www.usrds.org/2015/download/vol2_USRDS_ESRD_15.pdf.
6. Patel A, MacMahon S, Chalmers J, et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
7. Perkovic V, Heerspink HL, Chalmers J, et al Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–523.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.
9. Ismail-Beigi F, Craven T, Banerji MA, et al Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.
10. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(5):444–456.
11. Agarwal P. Management of diabetic kidney disease: recent advances. Indian J Endocrinol Metab. 2013;17(suppl 1):S55–S58.
12. Garber AJ, Abrahamson MJ, Barzilay JI, et al Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2016 Executive Summary. Endocr Pract. 2016;22(1):84–113.
13. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2(suppl):337–414.
14. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–713.
15. James PA, Oparil S, Carter BL, et al 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
16. Brenner BM, Cooper ME, de Zeeuw D, et al Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
17. Lewis EJ, Hunsicker LG, Clarke WR, et al Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259.
19. Eijkelkamp WB, Zhang Z, Remuzzi G, et al Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–1546.
20. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591.
21. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1):S58–S66.
22. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm.
23. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–1136.
24. AstraZeneca Pharmaceuticals. Prescribing information (BYDUREON® (exenatide extended-release) for injectable suspension (09/2015). http://www.azpicentral.com/bydureon/pi_bydureon.pdf#page=1.
25. AstraZeneca Pharmaceuticals. Prescribing information (02/2015): BYETTA (exenatide) injection. http://www.azpicentral.com/byetta/pi_byetta.pdf#page=1.
26. Novo Nordisk. Prescribing information (03/2015): Victoza® (liraglutide [rDNA origin] injection). http://www.novo-pi.com/victoza.pdf.
27. Sanofi. Prescribing information (08/2014): Lyxumia (lixisenatide). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002445/WC500140450.pdf.
28. GlaxoSmithKline. Prescribing information (05/2015): TANZEUM (albiglutide) for injection, for subcutaneous use. http://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF.
    29. Eli Lilly and Company. Prescribing information (03/2015): TRULICITY (dulaglutide) injection. http://pi.lilly.com/us/trulicity-uspi.pdf.
    30. AstraZeneca Pharmaceuticals LP. Prescribing information (08/2016): FARXIGA® (dapagliflozin) tablets, for oral use. http://www.farxiga.com.
    31. Boehringer Ingelheim Pharmaceuticals Inc. Prescribing information (12/2016):JARDIANCE® (empagliflozin) tablets. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf.
      32. Janssen Pharmaceuticals Inc. Prescribing information: INVOKANA® (canagliflozin) tablets (07/2016). http://www.invokana.com/prescribing-information.pdf.
      33. Boehringer Ingelheim Pharmaceuticals Inc. Prescribing information (08/2015):TRADJENTA® (linagliptin) tablets. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf.
      34. AstraZeneca Pharmaceuticals. Prescribing information (02/2015): ONGLYZA (saxagliptin) tablets. http://www.azpicentral.com/onglyza/pi_onglyza.pdf#page=1.
        35. Merck & Co. Inc. Prescribing information (08/2015): JANUVIA® (sitagliptin) tablets. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf.
          36. Takeda Pharmaceuticals U.S.A. Inc. Prescribing information (08/2015): Nesina (alogliptin) tablets. http://general.takedapharm.com/content/file.aspx?applicationcode=5D2277FD-CFC0-423C-B543-811D41F4771E&filetypecode=NESINAPI&cacheRandomizer=53bc3332-6373-446a-afbe-1adc4405561d.
            37. Chan JC, Scott R, Arjona Ferreira JC, et al Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–555.
            38. Arjona Ferreira JC, Marre M, Barzilai N, et al Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36(5):1067–1073.
            39. Arjona Ferreira JC, Corry D, Mogensen CE, et al Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013;61(4):579–587.
            40. Nowicki M, Rychlik I, Haller H, et al Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–1239.
            41. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–3468.
            42. Groop PH, Del Prato S, Taskinen MR, et al Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16(6):560–568.
            43. McGill JB, Sloan L, Newman J, et al Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–244.
            44. McGill JB, Barnett AH, Lewin AJ, et al Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diab Vasc Dis Res. 2014;11(1):34–40.
            45. Laakso M, Rosenstock J, Groop PH, et al Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38(2):e15–e17.
            46. McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. Diab Vasc Dis Res. 2015;12(4):249–257.
            47. Nakamura Y, Inagaki M, Shimizu T, et al Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract. 2013;123(1–2):46–51.
            48. Fujii Y, Abe M, Higuchi T, et al The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14(3):259–267.
            49. Sakai Y, Suzuki A, Mugishima K, et al Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. Intern Med. 2014;53(3):195–203.
            50. Cheng D, Fei Y, Liu Y, et al Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One. 2014;9(10):e111543.
            51. Ramirez G, Morrison AD, Bittle PA. Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease. Endocr Pract. 2013;19(6):1025–1034.
            52. Harashima SI, Ogura M, Tanaka D, et al Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract. 2012;66(5):465–476.
            53. Karasik A, Cohen CM, Chodik G, et al Urinary albumin secretion in type 2 diabetes patients (T2DM) with albuminuria treated with sitagliptin as add-on therapy to metformin: a real-world data study. Diabetes. 2014;63(suppl 1):A275.
            54. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab. 2012;14(7):596–600.
            55. Green JB, Bethel MA, Armstrong PW, et al TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
            56. Mosenzon O, Bhatt DA, Litwak L, et al Effect of saxagliptin on renal outcomes. Diabetes. 2014;63(suppl 1):A140.
            57. Laakso M, Rosenstock J, Groop PH, et al Linagliptin vs placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment. Diabetes. 2013;62:A281–282.
            58. von Eynatten M, Cooper M, Perkovic V, et al Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes. Diabetologia. 2013;56:S364.
            59. Inzucchi SE, Bergenstal RM, Buse JB, et al Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
            60. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850–886.
            61. Cooper ME, Perkovic V, McGill JB, et al Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441–449.
            Keywords:

            chronic kidney disease; CKD; diabetes mellitus; dipeptidyl peptidase-4 inhibitors; DPP-4; T2DM; type 2 diabetes mellitus

            Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.